Intec Pharma (NTEC) Receives European Patent Covering Accordion Pill Zaleplon

December 16, 2015 7:05 AM EST
Get Alerts NTEC Hot Sheet
Price: $9.63 --0%

Overall Analyst Rating:
    NEUTRAL (= Flat)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Intec Pharma Ltd. (NASDAQ: NTEC) announced that the Company has been informed by the European Patent Office (EPO) that a European patent will be granted December 23, 2015 on the Company's European Patent Application for a "Zaleplon gastroretentive drug delivery system."

The patent, number EP 237883, protects one of the Company's product candidates, Accordion Pill Zaleplon, that is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. The patent is currently scheduled to remain in force until October 19, 2029.

Zeev Weiss, CEO of Intec Pharma, said: "The new patent in Europe is an important addition to our IP portfolio. In November 2015, another European Patent Application was granted, which protects a method of producing Intec's Accordion Pill platform, and the Accordion Pill produced thereby. Expanding the IP portfolio of our Accordion Pill platform technology and of our pipeline products is an important goal. We are pleased to announce this second important addition to our IP portfolio in this quarter."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments